CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline
Kairos Pharma (NYSE:KAPA) CEO Dr. John Yu appeared on CEO.CA's 'Inside the Boardroom' to discuss significant clinical developments. The company reported promising safety data from their prostate cancer trial, demonstrating zero grade 3 or 4 toxicities, a notable improvement compared to standard treatments which show over 50% toxicity rates.
The interview highlighted upcoming efficacy data expected in September and potential expansion plans into lung cancer and other tumor types. The discussion was featured on CEO.CA, a leading investor social network platform for junior resource and venture stocks.
Kairos Pharma (NYSE:KAPA) Il CEO, Dr. John Yu, 猫 apparso su 'Inside the Boardroom' di CEO.CA per discutere importanti sviluppi clinici. L'azienda ha riportato promettenti dati di sicurezza dal loro trial sul cancro alla prostata, evidenziando l'assenza di tossicit脿 di grado 3 o 4, un miglioramento significativo rispetto ai trattamenti standard che mostrano tassi di tossicit脿 superiori al 50%.
L'intervista ha messo in luce i prossimi dati di efficacia previsti per settembre e i potenziali piani di espansione verso il cancro ai polmoni e altri tipi di tumore. La discussione 猫 stata trasmessa su CEO.CA, una piattaforma social leader per investitori focalizzata su azioni junior e venture.
Kairos Pharma (NYSE:KAPA) El CEO, Dr. John Yu, apareci贸 en 'Inside the Boardroom' de CEO.CA para hablar sobre importantes avances cl铆nicos. La compa帽铆a report贸 prometedores datos de seguridad de su ensayo sobre c谩ncer de pr贸stata, demostrando ausencia de toxicidades de grado 3 o 4, una mejora notable en comparaci贸n con los tratamientos est谩ndar que presentan tasas de toxicidad superiores al 50%.
La entrevista destac贸 los pr贸ximos datos de eficacia esperados para septiembre y los posibles planes de expansi贸n hacia el c谩ncer de pulm贸n y otros tipos de tumores. La charla fue presentada en CEO.CA, una plataforma social l铆der para inversores enfocada en acciones junior y de riesgo.
Kairos Pharma (NYSE:KAPA)鞚� CEO 臁� 鞙� 氚曥偓臧� CEO.CA鞚� 'Inside the Boardroom'鞐� 於滌棸頃橃棳 欷戩殧頃� 鞛勳儊 臧滊皽 靷暛鞚� 雲检潣頄堨姷雼堧嫟. 須岇偓電� 鞝勲靹犾晹 鞛勳儊 鞁滍棙鞐愳劀 鞙犽頃� 鞎堨爠靹� 雿办澊韯半ゼ 氤搓碃頄堨溂氅�, 3旮� 霕愲姅 4旮� 霃呾劚 氚橃潙鞚� 鞝勴榾 鞐嗢潓鞚� 氤挫棳 響滌 旃橂氩曥潣 50% 鞚挫儊鞚� 霃呾劚毳犾棎 牍勴暣 韥矊 臧滌劆霅� 瓴瓣臣毳� 雮橅儉雰堨姷雼堧嫟.
鞚疙劙敕办棎靹滊姅 9鞗旍棎 氚滍憸霅� 鞓堨爼鞚� 須姤 雿办澊韯�鞕� 韽愳晹 氚� 旮绊儉 膦呾枒 鞙犿槙鞙茧鞚� 頇曥灔 臧�電レ劚鞐� 雽�頃� 臧曥“頄堨姷雼堧嫟. 鞚� 雲检潣電� 欤茧媹鞏� 鞛愳洂 氚� 氩れ矘 欤检嫕 韴瀽鞛愲摛鞚� 鞙勴暅 欤检殧 靻岇厹 雱ろ姼鞗岉伂 頂岆灚韽检澑 CEO.CA鞐愳劀 靻岅皽霅橃棃鞀惦媹雼�.
Kairos Pharma (NYSE:KAPA) Le PDG, Dr John Yu, est intervenu dans l'茅mission 'Inside the Boardroom' de CEO.CA pour discuter d'importants d茅veloppements cliniques. La soci茅t茅 a rapport茅 des donn茅es de s茅curit茅 prometteuses issues de leur essai sur le cancer de la prostate, montrant une absence totale de toxicit茅s de grade 3 ou 4, une am茅lioration notable par rapport aux traitements standards qui pr茅sentent des taux de toxicit茅 sup茅rieurs 脿 50 %.
L'entretien a mis en avant les prochaines donn茅es d'efficacit茅 attendues en septembre ainsi que les plans potentiels d'expansion vers le cancer du poumon et d'autres types de tumeurs. La discussion a 茅t茅 diffus茅e sur CEO.CA, une plateforme sociale leader pour les investisseurs sp茅cialis茅e dans les actions junior et les entreprises en d茅marrage.
Kairos Pharma (NYSE:KAPA) CEO Dr. John Yu trat in CEO.CA's 'Inside the Boardroom' auf, um bedeutende klinische Entwicklungen zu besprechen. Das Unternehmen berichtete vielversprechende Sicherheitsdaten aus ihrer Prostatakrebs-Studie, die keinerlei Toxizit盲ten der Grade 3 oder 4 zeigten 鈥� eine bemerkenswerte Verbesserung gegen眉ber Standardbehandlungen, bei denen die Toxizit盲tsrate 眉ber 50 % liegt.
Im Interview wurden die bevorstehenden Wirksamkeitsdaten, die im September erwartet werden, sowie m枚gliche Expansionspl盲ne in Lungenkrebs und andere Tumorarten hervorgehoben. Die Diskussion wurde auf CEO.CA pr盲sentiert, einer f眉hrenden sozialen Investorenplattform f眉r Junior-Ressourcen- und Venture-Aktien.
- Zero grade 3 or 4 toxicities reported in prostate cancer trial, compared to over 50% with standard treatments
- Planned expansion into lung cancer and additional tumor types indicates growth potential
- Upcoming catalyst with efficacy data release in September
- Efficacy data not yet available, creating uncertainty around treatment effectiveness
- Multiple tumor type expansion plans may require significant additional resources
Toronto, Ontario--(Newsfile Corp. - July 28, 2025) - ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining explorers.
Founded in 2012, CEO.CA, a wholly owned subsidiary of , is one of the most popular free financial websites and apps in Canada and for investors globally - with industry leading audience engagement and mobile functionality. Millions of people visit CEO.CA each year to connect with investors from around the world, share knowledge and view impactful stories about stocks, commodities, and emerging companies.
Meet the Executive Shaping the Biotech Landscape
'Inside the Boardroom' is more than just an interview series - it's a chance to gain firsthand knowledge from industry leaders, understanding their vision, challenges, and strategy.
We caught up with Dr. John Yu, CEO of Kairos Pharma, Ltd. (NYSE American: KAPA) to discuss the company's safety data showing zero grade 3 or 4 toxicities (compared to over
Kairos Pharma
(NYSE American: KAPA)
Cannot view this video? Visit:
Tune in to 'Inside the Boardroom' each week and be part of the conversation that's shaping the business landscape. Visit CEO.CA or our YouTube page for hundreds more executive interviews from CEO.CA .
Interested in showcasing your company on 'Inside the Boardroom'? Get in touch with our team at [email protected] for further details and opportunities.
About CEO.CA
The leading community for investors & traders in junior resource & venture stocks. CEO.CA is one of the most popular free financial websites and apps in Canada and for small-cap/articles/market-capitalization-explained" title="Read: What Is Market Capitalization and How It Is Calculated" class="article-link" rel="noopener">small-cap investors globally -- with industry leading audience engagement and mobile functionality. Since 2012, CEO.CA has brought millions of investors together from over 164 countries to discuss their portfolio holdings and find new investment opportunities. Download our App on iOS or Android marketplace or visit us today at CEO.CA to set up your free account.
CEO.CA is a wholly owned subsidiary of .
For further information please contact:
CEO.CA
Email: [email protected]
Website:
Neither the TSX Venture Exchange ("TSXV"), OTC Best Market "(OTCQX") nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
The information regarding any issuer contained or referred to in any interviews conducted by CEO.CA has been furnished by such issuer directly, and neither CEO.CA nor any of its affiliates or principals assumes any responsibility for the accuracy or completeness of such information or for any failure by an issuer to ensure disclosure of events or facts which may affect the significance or accuracy of any such information.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release may include, but is not limited to, the objectives, goals, future plans, statements regarding exploration results and exploration and/or development plans of companies featured on the CEO.CA platform. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects, currency risk and the other risks involved in the applicable exploration and development industry, and those risks set out in the public documents of such companies filed on SEDAR or elsewhere from time to time. Undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. CEO.CA disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
To view the source version of this press release, please visit
FAQ
What safety results did Kairos Pharma (KAPA) report for its prostate cancer trial?
When will Kairos Pharma (KAPA) release efficacy data for its cancer treatment?
What are Kairos Pharma's (KAPA) expansion plans for its cancer treatment?
Who is the CEO of Kairos Pharma (KAPA)?
What makes Kairos Pharma's (KAPA) cancer treatment safety profile significant?
